# Trace Neuroscience

> Trace Neuroscience, Inc. is a biotechnology company developing genetic medicines for neurodegenerative diseases. Its lead investigational medicine, TRCN-1023, is designed to restore the function of the UNC13A protein, which is disrupted in most people living with amyotrophic lateral sclerosis (ALS). The company is running the FUNCtion ALS trial (NCT07674667), a randomized, double-blind, placebo-controlled Phase 1/2 study of TRCN-1023 delivered by intrathecal injection.

Trace Neuroscience does not publish a public developer portal, API documentation, or machine-readable API specifications. Its website (WordPress) exposes no llms.txt of its own; this file was generated by the API Evangelist enrichment pipeline from the company's public web presence and the ClinicalTrials.gov registry (fetched 2026-07-21).

## Company

- [Trace Neuroscience website](https://www.traceneuro.com): Corporate site covering About ALS, Our Focus, and Our Team
- [Clinical Trials](https://www.traceneuro.com/clinical-trials/): The company's clinical trials page
- [FUNCtion ALS trial (NCT07674667)](https://clinicaltrials.gov/study/NCT07674667): Phase 1/2 trial of TRCN-1023 in adults living with ALS, sponsored by Trace Neuroscience, Inc.

## Policies

- [Privacy Policy](https://www.traceneuro.com/privacy-policy/)
- [Terms of Service](https://www.traceneuro.com/terms-of-service/)